Company: HCWB
Filing Date: 2025-02-11
Form Type: PRE 14A
Source: 0001193125-25-024372
Chunk: 1

Company: HCW Biologics Inc.
Filing Date: 2025-02-11
Form: PRE 14A
Chunk 1
---
 maintain a listing of the Company’s common stock on the Nasdaq Capital Market) in a range from one-for-twenty (1:20) up to one-for-fifty (1:50), or anywhere between (the “Reverse Stock 
 Split”), while maintaining the number of authorized shares of common stock required for Nasdaq listing which is 150,000,000 shares, all as determined in the sole discretion of the Company’s Board of Directors;                                                                                                                       |

| 2. | To approve for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of our                                                                                                                                    
 common stock, or such lesser number of shares as the Board of Directors determines, pursuant to that certain Common Stock Purchase Agreement, dated _______, 2025 (the “Purchase Agreement”) and that certain Registration Rights Agreement, 
 dated _______, 2025 (the “Rights Agreement”) entered into in connection with an equity line of credit with _____________ (the “ELOC”);                                                                                                       |

| 3. | To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of the                                                                                                                                              
 Company’s common stock, par value $0.0001 per share (the “Common Stock”), upon conversion of up to $6,900,000 of principal amount of Senior Secured Notes issued by the Company to certain investors therein, including certain officers,          
 directors and stockholders of the Company (the “Noteholders”), pursuant to that certain Amended and Restated Senior Secured Note Purchase Agreement dated July 7, 2024, as amended by the First Amendment to Amended and Restated Senior           
 Secured Note Purchase Agreement dated September 30, 2024, and as it may be further amended in accordance with the Principal Terms for Conversion Amendment, which has been approved in principle by the Board of Directors and the Noteholders and 
 set forth on Appendix __ attached hereto (the “Principal Terms for Conversion”) and such additional terms and conditions not materially inconsistent with such Principal Terms for Conversion as the Board of Directors may hereafter approve.     |

| 4. | To transact such other business as may properly come before the Special Meeting or any adjournments or 
 postponements thereof.                                                                                 |

On or about [February 21, 2025], we will commence mailing a Notice of Special Meeting and
Proxy Statement to our stockholders along with instructions on how to access our Proxy Statement via the Internet and authorize a proxy to vote your shares online.